Article Text
PDF
Abstract
Objective To assess trends in antibiotic use across a large cohort of extremely low birth-weight (<1000 g; ELBW) infants admitted to academic and community neonatal intensive care units (NICUs) across the USA over a 13-year period.
Design Repeated cross-sectional cohort study.
Setting Premier Health Database, a comprehensive administrative database of inpatient encounters from academic and community hospitals across the US.
Patients ELBW inborn infants admitted to NICUs from 1 January 2009 to 31 December 2021.
Interventions N/A
Main outcome measures Absolute and relative changes in (1) proportion of ELBW infants with antibiotic exposure and (2) days of therapy (DOT) per 1000 patient days, over time. Average annual differences were estimated using generalised linear regression with 95% CI. Disposition trends were also measured.
Results Among 36 701 infants admitted to 402 NICUs, the proportion exposed to antibiotics was essentially unchanged (89.9% in 2009 to 89.3% in 2021; absolute reduction of −0.6%); generalised linear regression estimated an annual absolute difference of −0.3% (95% CI (−0.6%) to (−0.07%); p=0.01). DOT per 1000 patient days decreased from 337 in 2009 to 210 in 2021, a 37.8% relative difference and annual relative difference of −4.3% ((−5.2%) to (−3.5%); p<0.001). Mortality was unchanged during the study period.
Conclusions We found a substantial reduction in antibiotic DOT despite no substantive change in the proportion of infants exposed to antibiotics. This suggests the success of stewardship efforts aimed at antibiotic duration and highlight the need for improved approaches to identifying ELBW infants at highest risk of infection.
- Neonatology
- Intensive Care Units, Neonatal
- Infectious Disease Medicine
- Pharmacology
Data availability statement
Data may be obtained from a third party and are not publicly available.
Statistics from Altmetric.com
Data availability statement
Data may be obtained from a third party and are not publicly available.
Footnotes
X @dus10flan, @karen_puopolo
Contributors All authors were involved in conceptualising the study and critically reviewing the manuscript. DDF drafted the initial manuscript. AZB and DDF conducted the analysis and are responsible for the integrity of the data. DDF is guarantor.
Funding This work was supported by the Agency for Healthcare Research and Quality (K08 K08HS027468 to DF) and by Clinical Futures, a Research Institute Center of Emphasis at Children’s Hospital of Philadelphia. The funding organisations had no role in the design or conduct of the study; collection, management, analysis or interpretation of the data; preparation, review, or approval of the manuscripts; or decision to submit the manuscript for publication.
Competing interests None declared.
Provenance and peer review Not commissioned; externally peer-reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.